Juvenescence is a biopharmaceutical company that has raised USD $165 million since 2017 to build a pipeline of therapeutic assets to target aging, regeneration and the diseases of aging.
As people age, complex changes occur at the genomic, cellular and tissue level, from the accumulation of DNA damage to mitochondrial dysfunction and altered intercellular communication.
These changes, among others, cause the diseases of aging that affect the elderly, and the chronic illnesses that are the biggest burden on the healthcare system.
Aging is the largest health problem facing the world today; two-thirds of all deaths worldwide are as a result of the aging process, with many years of degeneration reducing quality of life before death.
Our work is based on novel scientific understanding of the underlying biological causes of aging, to create evidence-based therapeutics that can treat diseases of aging.
Juvenescence creates and partners with new companies with longevity-related therapeutics, by in-licensing compounds from academia and industry, or forming joint ventures with the foremost longevity scientists and leading research institutions.
Juvenescence aims to create a paradigm shift in addressing and treating disease.
Our goal is to extend both lifespan and healthspan, by developing therapeutics that slow aging and promote juvenescence (”the state or period of being young”).
Ultimately, Juvenescence aims to get therapeutics to patients, and eradicate life-shattering diseases that cause people to suffer until death.
Juvenescence leverages its world-class team to translate rigorous science into disease-modifying therapeutics.
Our growing pipeline of therapeutic assets targets fundamental aging, regeneration, and the diseases of aging. Click below to the full pipeline to learn more about each company.
Insilico Medicine secures $37M in Series B funding led by Qiming Venture Partners
Insilico Medicine, a pioneer in next-generation artificial intelligence technology for drug discovery, recently completes a USD $37 million funding round led by Qiming Venture Partners, joined by Eight Roads, F-Prime Capital, Lilly Asia Ventures, Sinovation Ventures, Baidu Ventures, Pavilion Capital, BOLD Capital Partners and other investors including series A investors.Read more
Insilico Medicine uses AI to design novel molecules in 21 days
Juvenescence is impressed by Insilico Medicine’s recent article in Nature Biotech, highlighting their ability to use deep learning for de novo small-molecule design. They have developed a deep generative model, generative tensorial reinforcement learning (GENTRL) to discover potent inhibitors of discoidin domain receptor 1 (DDR1), a kinase target implicated in…Read more
Please complete the form below to get in touch with the Juvenescence team.